Selective Metalloenzyme Inhibitors for CYP11B2 Aldosterone Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for aldosterone-related diseases, such as hypertension and fibrosis, face challenges due to the lack of selective inhibitors for CYP11B2, the enzyme responsible for aldosterone biosynthesis, leading to unwanted inhibition of related enzymes like CYP11B1 and potential clinical toxicity.
Innovation Solution
Development of selective metalloenzyme inhibitors, particularly targeting CYP11B2, which utilize specific metal-binding groups to block aldosterone production without affecting CYP11B1, thereby addressing MR-independent inflammatory and fibrotic states.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If nonselective MR antagonists like spironolactone are used to block aldosterone effects, then morbidity and mortality are reduced, but off-target effects on progesterone and androgen receptors occur causing gynaecomastia
Solution Approach 1:
The patent applies local quality by designing inhibitors with specific metal-binding groups that selectively target the heme iron in CYP11B2's active site, creating a localized and specific interaction that spares other enzymes and receptors from off-target effects
Solution Approach 2:
The metal-binding group acts as an intermediary that mediates selective inhibition of CYP11B2 by specifically coordinating with the heme iron, enabling precise enzyme targeting without the need for nonselective MR antagonism
2Reliability
If CYP11B2 inhibition is achieved using Osilodrostat, then aldosterone production is blocked, but CYP11B1 is also inhibited causing clinical toxicity
Solution Approach 1:
The patent applies local quality by designing inhibitors with specific metal-binding groups that selectively target the heme iron in CYP11B2's active site, creating a localized and specific interaction that spares other enzymes and receptors from off-target effects
Solution Approach 2:
The patent applies parameter changes by modifying the chemical structure of inhibitors to include specific metal-binding groups with optimized binding characteristics, changing the selectivity parameter to preferentially inhibit CYP11B2 over CYP11B1
3Reliability
If MR antagonism is used to treat aldosterone-related diseases, then aldosterone effects are blocked, but renin and aldosterone levels increase exacerbating MR-independent effects
Solution Approach 1:
The patent applies preliminary action by using CYP11B2 inhibitors to block aldosterone synthesis before aldosterone can bind to and activate MR, preventing the downstream effects of aldosterone excess without triggering compensatory renin and aldosterone elevation
Solution Approach 2:
The metal-binding group acts as an intermediary that mediates selective inhibition of CYP11B2 by specifically coordinating with the heme iron, enabling precise enzyme targeting without the need for nonselective MR antagonism
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The inhibitors effectively reduce aldosterone levels, mitigating harmful effects on the body while minimizing off-target enzyme inhibition, thus providing a safer and more targeted treatment for aldosterone-related diseases.
Implementation Method 1
compounds which inhibit the activity of a metalloenzyme by coordination of a metal-binding group of the compound to the metal in the active site of the metalloenzyme
Implementation Method 2
CYP11B2 is a mitochondrial cytochrome P450 enzyme which which converts 11-deoxycorticosterone to aldosterone
Implementation Method 3
CYP11B2 is a mitochondrial cytochrome P450 enzyme which which converts 11-deoxycorticosterone to aldosterone
Data Source
AI summary
Provided are compounds having metalloenzyme modulating activity, and methods of treating diseases, disorders, or symptoms thereof mediated by such metalloenzymes. In some embodiments, a provided compound is a compound of Formula I,or a pharmaceutically acceptable salt thereof. In some embodiments, a provided method is a method of alleviating or abating a disorder or disease associated with aldosterone synthase (CYP11B2) or ameliorating a symptom thereof.